Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1982 Jun;47(6):521–526. doi: 10.1136/hrt.47.6.521

Acute prolongation of myocardial refractoriness by sotalol.

D H Bennett
PMCID: PMC481177  PMID: 7082500

Abstract

Sotalol, a beta adrenoceptor antagonist, was given intravenously to 15 patients with accessory atrioventricular pathways during intracardiac electrophysiological studies. Eleven patients had the Wolff-Parkinson-White syndrome and four patients had concealed left sided accessory pathways. Four patients were restudied while receiving oral sotalol. In contrast to the actions typical of beta blocking agents, intravenous sotalol prolonged the effective refractory periods of the ventricles and accessory pathways and reduced the ventricular response to atrial fibrillation in the patients with the Wolff-Parkinson-White syndrome. Similar results were obtained with oral administration. These findings support the observation that sotalol, unlike other beta blocking agents. causes acute prolongation of the myocardial action potential and suggest that this action might be of therapeutic use.

Full text

PDF
521

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bennett D. H. Disopyramide in patients with the Wolff-Parkinson-White syndrome and atrial fibrillation. Chest. 1978 Dec;74(6):624–628. doi: 10.1378/chest.74.6.624. [DOI] [PubMed] [Google Scholar]
  2. Denes P., Cummings J. M., Simpson R., Wu D., Amat-Y-Leon F., Dhingra R., Rosen K. M. Effects of propranolol on anomalous pathway refractoriness and circus movement tachycardias in patients with preexcitation. Am J Cardiol. 1978 May 22;41(6):1061–1067. doi: 10.1016/0002-9149(78)90858-5. [DOI] [PubMed] [Google Scholar]
  3. Di Biase M., Brindicci G., Rizzon P. Effects of prindolol on impulse formation and conduction in man. J Electrocardiol. 1977 Jan;10(1):45–50. doi: 10.1016/s0022-0736(77)80030-7. [DOI] [PubMed] [Google Scholar]
  4. Edvardsson N., Hirsch I., Emanuelsson H., Pontén J., Olsson S. B. Sotalol-induced delayed ventricular repolarization in man. Eur Heart J. 1980 Oct;1(5):335–343. doi: 10.1093/eurheartj/1.5.335. [DOI] [PubMed] [Google Scholar]
  5. Edvardsson N., Olsson S. B. Effects of acute and chronic beta-receptor blockade on ventricular repolarisation in man. Br Heart J. 1981 Jun;45(6):628–636. doi: 10.1136/hrt.45.6.628. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gallagher J. J., Pritchett E. L., Sealy W. C., Kasell J., Wallace A. G. The preexcitation syndromes. Prog Cardiovasc Dis. 1978 Jan-Feb;20(4):285–327. doi: 10.1016/0033-0620(78)90015-4. [DOI] [PubMed] [Google Scholar]
  7. Neuvonen P. J., Elonen E. Sotalol, prolonged Q-Tc interval, and tachyarrhythmias. Lancet. 1982 Jan 9;1(8263):106–106. doi: 10.1016/s0140-6736(82)90241-0. [DOI] [PubMed] [Google Scholar]
  8. Robinson C., Birkhead J., Crook B., Jennings K., Jewitt D. Clinical electrophysiological effects of atenolol--a new cardioselective beta-blocking agent. Br Heart J. 1978 Jan;40(1):14–21. doi: 10.1136/hrt.40.1.14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Rosenbaum M. B., Chiale P. A., Halpern M. S., Nau G. J., Przybylski J., Levi R. J., Lázzari J. O., Elizari M. V. Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol. 1976 Dec;38(7):934–944. doi: 10.1016/0002-9149(76)90807-9. [DOI] [PubMed] [Google Scholar]
  10. Rosenbaum M. B., Chiale P. A., Ryba D., Elizari M. V. Control of tachyarrhythmias associated with Wolff-Parkinson-White syndrome by amiodarone hydrochloride. Am J Cardiol. 1974 Aug;34(2):215–223. doi: 10.1016/0002-9149(74)90200-8. [DOI] [PubMed] [Google Scholar]
  11. Seides S. F., Josephson M. E., Batsford W. P., Weisfogel G. M., Lau S. H., Damato A. N. The electrophysiology of propranolol in man. Am Heart J. 1974 Dec;88(6):733–741. doi: 10.1016/0002-8703(74)90283-x. [DOI] [PubMed] [Google Scholar]
  12. Sellers T. D., Jr, Campbell R. W., Bashore T. M., Gallagher J. J. Effects of procainamide and quinidine sulfate in the Wolff-Parkinson-White syndrome. Circulation. 1977 Jan;55(1):15–22. doi: 10.1161/01.cir.55.1.15. [DOI] [PubMed] [Google Scholar]
  13. Singh B. N., Vaughan Williams E. M. A third class of anti-arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol. 1970 Aug;39(4):675–687. doi: 10.1111/j.1476-5381.1970.tb09893.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Singh B. N., Vaughan Williams E. M. The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol. 1970 Aug;39(4):657–667. doi: 10.1111/j.1476-5381.1970.tb09891.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Spurrell R. A., Krikler D. M., Sowton E. Concealed bypasses of the atrioventricular mode in patients with paroxysmal supraventricular tachycardia revealed by intracardiac electrical stimulation and verapamil. Am J Cardiol. 1974 May 6;33(5):590–595. doi: 10.1016/0002-9149(74)90247-1. [DOI] [PubMed] [Google Scholar]
  16. Ward D. E., Camm A. J., Spurrell R. A. The acute cardiac electrophysiological effects of intravenous sotalol hydrochloride. Clin Cardiol. 1979 Jun;2(3):185–191. doi: 10.1002/clc.4960020303. [DOI] [PubMed] [Google Scholar]
  17. Williams E. M., Raine A. E., Cabrera A. A., Whyte J. M. The effects of prolonged beta-adrenoceptor blockade on heart weight and cardiac intracellular potentials in rabbits. Cardiovasc Res. 1975 Sep;9(5):579–592. doi: 10.1093/cvr/9.5.579. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES